Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with <i>EGFR</i>-mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study.

American Society of Clinical Oncology (ASCO) - Tập 32 Số 15_suppl - Trang 8017-8017 - 2014
Yi‐Long Wu1, James Chih‐Hsin Yang2, Dong‐Wan Kim3, Wu‐Chou Su4, Myung‐Ju Ahn5, Ki Hyeong Lee6, Johan Vansteenkiste7, Li Zhang8, Enriqueta Felip9, Bin Peng10, Ying Gong10, Sylvia Zhao10, Taro Amagasaki11, Mikhail Akimov12, Daniel Shao-Weng Tan13
1Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou, China
2National Taiwan University Hospital, Taipei, Taiwan
3Seoul National University Hospital, Seoul, South Korea
4National Cheng Kung University Hospital, Taipei, Taiwan
5Samsung Medical Center, Seoul, South Korea
6Asan Medical Center, Seoul, South Korea
7University Hospital KU Leuven, Leuven, Belgium
8Sun Yat-sen University Cancer Center, Guangzhou, China
9Vall d'Hebron University Hospital, Barcelona, Spain
10China Novartis Institutes for Biomedical Research, Shanghai, China
11Novartis Pharma KK, Tokyo, Japan
12Novartis Pharma AG, Basel, Switzerland
13National Cancer Centre, Singapore, Singapore

Tóm tắt

Từ khóa


Tài liệu tham khảo

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 32 Số 15_suppl

8017-8017

Thông tin tác giả